Business Description
OncoCyte Corp
NAICS : 325412
SIC : 2834
Compare
Compare
Traded in other countries / regions
7OC.Germany0KCC.UKOCX.USA Description
OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers. Geographically operation of the group is carried through the United States, and it earns revenue from the sale of diagnostic tests.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 8.63 | |||||
| Equity-to-Asset | 0.49 | |||||
| Debt-to-Equity | 0.05 | |||||
| Debt-to-EBITDA | -0.06 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -2.67 | |||||
| Beneish M-Score | -0.69 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -26 | |||||
| 3-Year EPS without NRI Growth Rate | -19.7 | |||||
| 3-Year FCF Growth Rate | -11.6 | |||||
| 3-Year Book Growth Rate | 103.4 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 46.85 | |||||
| 9-Day RSI | 45.8 | |||||
| 14-Day RSI | 46.88 | |||||
| 6-1 Month Momentum % | -33.51 | |||||
| 12-1 Month Momentum % | -56.6 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.83 | |||||
| Quick Ratio | 2.83 | |||||
| Cash Ratio | 2.51 | |||||
| Days Inventory | 12.68 | |||||
| Days Sales Outstanding | 75.58 | |||||
| Days Payable | 87.78 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -31.4 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | -8.05 | |||||
| Operating Margin % | -707.4 | |||||
| Net Margin % | -788.06 | |||||
| ROE % | -82.55 | |||||
| ROA % | -39.75 | |||||
| ROIC % | -44.65 | |||||
| ROC (Joel Greenblatt) % | -636.25 | |||||
| ROCE % | -43.33 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 4.97 | |||||
| PB Ratio | 0.62 | |||||
| EV-to-EBIT | -0.29 | |||||
| EV-to-EBITDA | -0.32 | |||||
| EV-to-Revenue | 2.33 | |||||
| EV-to-Forward-Revenue | 10.19 | |||||
| EV-to-FCF | -0.4 | |||||
| Earnings Yield (Greenblatt) % | -342.86 |
How OncoCyte Corp (FRA:7OC) Makes Its Money
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Annualized Return %
Total Annual Return %
Executives
Details
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 7.452 | ||
| EPS (TTM) (€) | -0.592 | ||
| Beta | 0.36 | ||
| Volatility % | 50.54 | ||
| 14-Day RSI | 46.88 | ||
| 14-Day ATR (€) | 0.026403 | ||
| 20-Day SMA (€) | 0.3764 | ||
| 12-1 Month Momentum % | -56.6 | ||
| 52-Week Range (€) | 0.22 - 1.6 | ||
| Shares Outstanding (Mil) | 118.64 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
OncoCyte Corp Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||
OncoCyte Corp Stock Events
| Event | Date | Price(€) | Daily Change % | ||
|---|---|---|---|---|---|
| No Event Data | |||||
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||